The market performance of the autoimmune drug market has been mounting and rapidly growing in recent years, with enormous potential and frequent blockbuster drugs. There were 3 autoimmune drugs among the top 4 in the annual global drug sales rankings, and even the strong oncology drug market had to "give in" in the face of the overwhelming momentum of the autoimmune drug market.

The 2017 sales of the top 11 autoimmune drugs were USD 50.73 billion.

TNFα inhibitors have indications across a dozen of diseases associated with autoimmunity, and became the king variety on the autoimmune drug market as led by Humira. The total sales of the 5 anti-TNFα monoclonal antibodies reached USD 37.49 billion in 2017, accounting for 73.9% of the total. However, there have been marketed generic drugs of Enbrel and Remicade, and even a drug with strong sales like Humira could not stop the decline of the variety’s future market after years of domination.

With impacts from generic drugs after patent expiration of original drugs and the strong rise of non-anti-TNFα monoclonal antibodies, the internal and external troubles result in anti-TNFα monoclonal antibodies to be overwhelmed.

The launch of anti-IL-6 monoclonal antibodies and JAK inhibitors that are indicated for rheumatoid arthritis and anti-IL-23/17A monoclonal antibodies that are indicated for psoriasis has slowly broken the status quo of anti-TNFα monoclonal antibodies’ domination, and those drugs are rapidly growing, with potential of becoming blockbuster drugs: their sales rose from USD 7.12 billion in 2015 to USD 13.24 billion in 2017, to account for 26.1%, and their proportion is expected to reach about 35% in 2022.

Keep reading: Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

Register as Visitor to CPhI China 2018!